Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

Benzinga · 3d ago
Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.